AbbVie Inc.
Income Statement
| Line Item | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.46B | $12.31B | $14.30B | $13.93B | $13.87B | $12.23B | $15.12B | $14.81B |
| Cost of Revenue | $4.20B | $4.09B | $5.70B | $6.49B | $4.24B | $3.99B | $4.17B | $5.02B |
| Gross Profit | $10.26B | $8.22B | $8.60B | $7.44B | $9.63B | $8.24B | $10.95B | $9.79B |
| Gross Margin | 70.9% | 66.7% | 60.1% | 53.4% | 69.4% | 67.4% | 72.4% | 66.1% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $3.38B | $3.32B | $3.19B | $3.37B | $3.27B | $3.04B | $3.42B | $3.30B |
| Operating Income | $4.00B | $2.80B | $3.20B | $2.28B | $4.51B | $2.77B | $5.50B | $4.60B |
| Operating Margin | 27.6% | 22.7% | 22.3% | 16.4% | 32.5% | 22.6% | 36.4% | 31.1% |
| Interest Expense | $726.0M | $660.0M | $564.0M | $555.0M | $552.0M | $553.0M | $566.0M | $560.0M |
| Pretax Income | $2.15B | $1.76B | $1.21B | $1.95B | $2.61B | $475.0M | $2.97B | $4.40B |
| Income Tax Expense | $773.0M | $383.0M | $388.0M | $172.0M | $583.0M | $234.0M | $493.0M | $448.0M |
| Net Income | $1.37B | $1.37B | $822.0M | $1.78B | $2.02B | $239.0M | $2.47B | $3.95B |
| Net Margin | 9.5% | 11.1% | 5.7% | 12.8% | 14.6% | 2.0% | 16.4% | 26.7% |
| EPS (Basic) | $0.77 | $0.77 | $0.46 | $1.00 | $1.14 | $0.13 | $1.39 | $2.22 |
| EPS (Diluted) | $0.77 | $0.77 | $0.46 | $1.00 | $1.14 | $0.13 | $1.38 | $2.21 |
| Shares Outstanding (Basic) | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B |
| Shares Outstanding (Diluted) | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.78B | 1.78B | 1.78B |
| Dividends Per Share | $1.55 | $1.55 | $1.55 | $1.48 | $1.48 | $1.48 | $1.48 | $1.41 |